Letters to the Editor

Frontline isocitrate dehydrogenase inhibitor therapy in isocitrate dehydrogenase-mutated myelodysplastic neoplasms

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Haematologica Early view Nov 5, 2026 https://doi.org/10.3324/haematol.2026.301769